Manufacturing capabilities at Brijdol Biopharma include the production of Enzymes, Probiotics, Biotech Intermediates, and Biological Active Pharmaceutical Ingredients (APIs). In addition to in-house development and manufacturing of novel biotech-derived products, Brijdol also offers contract research and manufacturing services to other companies.
We manufacture a wide range of injectable formulations, including vials and ampoules, adhering to stringent World Health Organization (WHO) Good Manufacturing Practices (GMP). The company's Research & Development department focuses on developing formulations for new injectable drugs and conducts rigorous stability testing and analysis to ensure product quality and safety.
Our drug discovery efforts encompass the identification and development of novel drug candidates, including target identification and validation, and lead compound optimization. In addition to drug discovery, the company also develops innovative diagnostic tools and assays. The company's preclinical research program includes in vitro and in vivo studies to evaluate the safety and efficacy of drug candidates.
Stringent quality control measures: Ensuring the safety, efficacy, and quality of all products. Compliance with regulatory requirements (e.g., FDA, EMA).
Commitment to improving global health. Focus on providing access to affordable and quality healthcare. Sustainable and ethical business practices.
